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Introduction: Cl-inhibitor (Cl-INH) is used for the treatment 
of patients with hereditary angioedema. Recently, beneficial 
effects of high-dose Cl-INH treatment on myocardial ische-
mia have been reported in animal models and in man. We in-
vestigated the pharmacokinetic behavior ofCl-INH in patients 
with acute myocardial infarction (AMI) to calculate the 
amount ofCl-INH required for optimal efficacy. 
Methods: Twenty-two patients received an intravenous load-
ing dose followed by 48 hours of continuous infusion of C 1-
INH. Changes in the endogenous production ofCl-INH were 
checked in sixteen control patients with AMI. A two-compart-
ment model was used to estimate the Fractional Catabolic Rate 
(FCR), the Transcapillary Escape Rate (TER) and the Extra-
vascular Return Rate (ERR) constants of Cl-INH. Software 
that was specially designed for solving a system of dynamic 
differential and algebraic equations was used to fit the experi-
mental data against the three-parameter model. 
Results: With fixed values for TER and ERR (0.014 and 0.018 
h·' respectively), 20 of the 22 cases gave well-determined 
values for FCR, and simultaneous fitting resulted in an FCR of 
0.011± 0.001 h·' (median ± 95% confidence interval) versus 
0.025 h·' as reported in healthy controls. Simultaneous estima-
tion of all three parameters resulted in ill-defined values of 
TER and ERR, but left the median value ofFCR unchanged. 
Conclusion: Dose calculation of C 1-INH in patients treated 
with massive doses of Cl-INH requires turnover parameters 
different from those found in healthy subjects, possibly due to 
suppression of continuous Cl-INH consumption by target pro-
teases. 
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Background: High sensitivity CRP (hs-CRP) is considered as 
an important risk factor for coronary heart disease and intro-
duction, as a routine laboratory parameter is obvious. To 
report reliable CRP results regardless of the clinical context, it 
is of course most practical if one CRP method is used for the 
complete measuring range. We report here the evaluation of a 
hs-CRP method for the Beckman Synchron LX®20 (measur-
ing range 0.2-380 mg/I). 
Methods: Routine C-reactive protein (CRP) and hs-CRP were 
both measured on the Beckman Synchron LX®20. A special 
measuring device Synchron LX®20 PRO, was implemented to 
allow analysis of the hs-CRP method. The hs-CRP method 
was compared (521 samples) with the BNA from Dade 
Behring and the IMMAGE from Beckman Coulter. The influ-
ence of sample turbidity, a known major problem of the pre-
sent Synchron LX®20 CRP method, was also examined. 
Results. Total imprecision (CV) remained less than 8% over the 
whole measuring range. In the low range (0-10 mg/1) very good 
agreement was found between the different hs-CRP methods 
based on Deming regression analysis and Bland-Altman plots, 
whereas in the high range (above 100 mg/1) large discrepancies 
between the methods were seen. The Synchron LX®20 PRO 
hs-CRP method was not influenced by sample turbidity. 
Conclusions. Based on its performance in the low range, the 
Synchron LX®20 PRO hs-CRP method appears suitable for 
cardiovascular risk stratification. However, to allow the use of 
one CRP method for the complete measuring range, standardi-
sation should be improved, especially in the high range. 
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Introduction: Epidemiological studies have shown that mo-
derate intake of red wine reduces the risk of coronary heart 
disease. It has been proposed that the antitherogenic effects is 
due to the antioxidant effect of polyphenols and ethanol. We 
have determined the reaction rates of superoxide with four 
different polyphenols and ethanol. 
Methods: The superoxide reaction rates were determined at 
37°C and pH 7.4 using competitive spin trapping and Electron 
Paramagnetic Resonance (EPR) spectroscopy. 
Results and discussion: Ethanol did not scavenge superoxide. 
For the polyphenols we do find significant superoxide scav-
enging. For Catechine, Epicatechine, Gallic Acid and Querce-
tine we find rate constants of respectively 2.3 104, 2.2 104, 2.3 
103 and 1.7 104 (M.s.)·1• In order to estimate the capacity of 
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the polyphenols to exert an antioxidant effect in vivo, it is nec-
essary to see them in perspective of their respective plasma 
concentrations and a known antioxidant, e.g. vitamin C. The 
plasma concentration of the polyphenols is reported to be in 
the low nM range. In comparison: Vitamin C has a rate con-
stant of2.7 105 (M.s)·' and a plasma concentration of approxi-
mately 10 - 100 µmol/1. Therefore, the in vivo antioxidant 
effect of red wine polyphenols and ethanol is negligible in 
comparison to vitamin C. 
Conclusions: At concentrations found in vivo, the antioxidant 
effect of red wine polyphenols and ethanol is negligible. The 
antiatherogenic effects must be caused by a mechanism other 
than direct scavenging of superoxide. 
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